Contents Link Navigation Link

Targeting, Attacking, and Eradicating Cancers®

JX-900 Series

Targeting, Attacking, and Eradicating Cancers®

Western Reserve Backbone Pipeline

JX-929 is derived from Western Reserve strain vaccinia virus. JX-929’s tumor selectivity has been optimized through deletion of thymidine kinse (TK) and vaccinia growth factor (VGF).JX-929 has been administered as a monotherapy to patients with breast, colorectal, and pancreatic cancer via intratumoral & intravenous injections in a Phase 1, dose escalation clinical trial. This Phase 1 study showed delivery to and replication within tumors1 both IT and IV.


JX-970 is also derived from a Western Reserve strain vaccinia virus and utilizes the same tumor selectivity mechanisms as JX-929. In addition, it expresses GM-CSF to stimulate immune reponses.In nonclinical studies, the JX-970 backbone exerted a tumor debulking effect and at the same time demonstrated a selective preference for tumor tissues2.

Key References:1Thorne et al., Journal of Clinical Investigation 2007
2Zeh et al., Molecular Therapy 2015 (

JX-900 SeriesJX-900 SeriesJX-900 Series
JX-900 (VVDD)

VVDD Platform: Next-gen enhanced oncolytic immunotherapy

JX-900 (VVDD) Series
  • JX-900 is a series of modified vaccinia vaccine (Western Reserve strain) with enhanced oncolytic potency
  • Attenuation via “Double-Deletion” : TK (thymidine kinase) & VGF (vaccinia growth factor) gene inactivation
  • JX-929 (vvDD expressing CD for 5-FU prodrug) experience in solid tumors (CRC and melanoma)
  • JX-970 (vvDD expressing GM-CSF) ready for clinical use by 2H 2018